Organic sales grew 2% year-over-year in Q2 2026, with margin expansion and adjusted EBITDA up 5%. Merger preparations with Axalta are on track, with substantial synergy targets and a shareholder vote set for August. Free cash flow and working capital efficiency remain strong.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.